comparemela.com
Home
Live Updates
Neal Shore - Breaking News
Pages:
2
3
4
5
6
7
8
Latest Breaking News On - Neal shore - Page 1 : comparemela.com
Pluvicto May Slow Progression Earlier in Advanced Prostate Cancer
Treatment with Pluvicto following ARPI resulted in favorable progression and response outcomes in PSMA-positive mCRPR.
United states
Dana farber cancer institute
Xiaox wei
Drug administration
American urological association annual meeting
Carolina urologic research center
Neal shore
Erleada, ADT One-Two Punch in Prostate Cancer Treatment
The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer.
United states
Carolina urologic research center
National cancer institute
American urological association annual meeting
Drug administration
National cancer
Urological association annual meeting
Neal shore
Carolina urologic research
J&J: encouraging results in prostate cancer
Johnson & Johnson has announced results from an open-label Phase 2 study evaluating adjuvant treatment with Erleada and androgen deprivation therapy in patients with HRLPC who have undergone.
Neal shore
Chief medical officer
Surgical oncology
Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology
Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.
Carolina urologic research center
Neal shore
Medical officer
Genesiscare united states
Atlantic urology clinics
Bacillus calmette
Urothelial cancer
Multidisciplinary care
Enfortumab vedotin ejfv padcev
Checkmate 901
V 302 keynote a39 nct04223856
Dr Shore on Key Clinical Trial Data in Biochemically Recurrent Prostate Cancer
Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.
Carolina urologic research center
Neal shore
Medical officer
Genesiscare united states
Atlantic urology
Biochemical recurrence
Prostate cancer
Phase 3 embark trial nct02319837
vimarsana © 2020. All Rights Reserved.